Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.
Conget I, Castaneda J, Petrovski G, Guerci B, Racault AS, Reznik Y, Cohen O, Runzis S, de Portu S, Aronson R; OpT2mise Study Group. Conget I, et al. Among authors: aronson r. Diabetes Technol Ther. 2016 Jan;18(1):22-8. doi: 10.1089/dia.2015.0159. Epub 2015 Aug 4. Diabetes Technol Ther. 2016. PMID: 26241790 Free PMC article. Clinical Trial.
Response to Letter to the Editor Regarding OpT2mise Study.
Conget I, Aronson R, Cohen O, Reznik Y. Conget I, et al. Among authors: aronson r. Diabetes Technol Ther. 2016 Jul;18(7):448. doi: 10.1089/dia.2016.0081. Epub 2016 Apr 4. Diabetes Technol Ther. 2016. PMID: 27043892 No abstract available.
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy-Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators. Rosenstock J, et al. Among authors: aronson r. Diabetes Care. 2016 Aug;39(8):1318-28. doi: 10.2337/dc16-0014. Epub 2016 May 23. Diabetes Care. 2016. PMID: 27222510 Free article. Clinical Trial.
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators. Rosenstock J, et al. Among authors: aronson r. Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15. Diabetes Care. 2016. PMID: 27527848 Clinical Trial.
298 results